[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Zhonghua Nei Ke Za Zhi
; 57(5): 351-354, 2018 May 01.
Article
en Zh
| MEDLINE
| ID: mdl-29747291
ABSTRACT
To explore the efficacy of sorafenib combined with chemotherapy and donor lymphocyte infusion (DLI) in patients with FLT3-positive acute myeloid leukemia (AML) relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Of the 14 patients relapsed after allo-HSCT, 9 achieved complete remission after salvage therapy of sorafenib combined with chemotherapy and DLI, 6 with complete molecular remission, 2 with partial remission, and 3 with no response. With a median follow up of 220 (range, 30-1 782) days after post-transplantation relapse, 7 patients were still alive and 7 died. Salvage therapy of sorafenib combined with chemotherapy and DLI shows a decent therapeutic effect for FLT3-positive AML relapsed after allo-HSCT.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Compuestos de Fenilurea
/
Leucemia Mieloide Aguda
/
Inmunoterapia Adoptiva
/
Terapia Recuperativa
/
Niacinamida
/
Trasplante de Células Madre Hematopoyéticas
/
Antineoplásicos
Límite:
Humans
Idioma:
Zh
Revista:
Zhonghua Nei Ke Za Zhi
Año:
2018
Tipo del documento:
Article
País de afiliación:
China